Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight
Clinical Endocrinology · 2026-02 · 104 (2) · 130-138
DOI: 10.1111/cen.70059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 24.11.2025. Verfasst von Niki Jalava und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine, University of Turku, Turku, Southwest Finland, Finland. Hauptthemen laut MEDLINE: Glucose, Bone and Bones, Body Weight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was supported by grants from the Research Council of Finland (grant# 325498 to K.K.I., #335446 to K.A.V.), Finnish Diabetes Research Foundation (K.A….
Abstract (Originalsprache)
Objective
Bone is a target for diabetic complications, but the impact of metabolic changes on bone metabolism is less understood. Bones participate in energy metabolism by via secreted osteokines. Glucose ingestion reduces bone resorption, but the effects on osteokines remain unknown. Further, it is not known whether the response is altered in obesity. The objective of the study was to compare responses in circulating levels of osteokines to glucose ingestion between participants with normal weight (BMI < 26 kg/m 2 , n = 22) and obesity (BMI > 28 kg/m 2 , n = 27) (age = 21–54 yr).
Measurements
C‐terminal telopeptide of collagen I (b‐CTX‐I), total osteocalcin (OC), sclerostin, fibroblast growth‐factor 23 (cFGF23), uncarboxylated OC, and lipocalin 2 (LCN2) at baseline and after 2 h oral glucose tolerance test (OGTT).
Results
OGTT resulted in a significant decrease in bone resorption, median decrease in b‐CTX‐I was 42% ( p < 0.0001) in both groups. Osteokine levels were modestly but statistically significantly decreased, OC decreased by 11% ( p < 0.0001) and FGF23 by 14% ( p = 0.007) in both groups, while uncarboxylated OC decreased by 1.2% ( p < 0.0001) and sclerostin by 7.8% ( p = 0.032) only in participants with obesity. Although the differences in responses between the groups were not statistically significant, we observed a tendency for less pronounced effect on b‐CTX‐I ( p = 0.052) and a greater effect on OC ( p = 0.051) in participants with obesity compared to normal weight.
Conclusion
Osteokines respond rapidly to oral glucose regardless of body weight. Orally‐administered glucose affects not only bone turnover but can also suppress bone endocrine functions. Furthermore, obesity may influence the effect of oral glucose on circulating levels of bone turnover markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedicine, University of Turku, Turku, Southwest Finland, Finland.
- Turku PET Centre, University of Turku, Turku, Southwest Finland, Finland.
- Turku PET Centre, Turku University Hospital, Turku, Southwest Finland, Finland.
ORCID-Profile: Niki Jalava, Terhi J Heino, Pirjo Nuutila, Kirsi A Virtanen, Kaisa K Ivaska
Förderung
- This study was supported by grants from the Research Council of Finland (grant# 325498 to K.K.I., #335446 to K.A.V.), Finnish Diabetes Research Foundation (K.A…
Zitieren
APA
Jalava, N., Heino, T. J., Nuutila, P., Virtanen, K. A., & Ivaska, K. K. (2026). Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight. Clinical Endocrinology, 104(2), 130-138. https://doi.org/10.1111/cen.70059
Vancouver
Jalava N, Heino TJ, Nuutila P, Virtanen KA, Ivaska KK. Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight. Clinical Endocrinology. 2026;104(2):130-138. doi:10.1111/cen.70059
BibTeX
@article{Jalava2026,
author = {Jalava, Niki and Heino, Terhi J and Nuutila, Pirjo and Virtanen, Kirsi A and Ivaska, Kaisa K},
title = {Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight},
journal = {Clinical Endocrinology},
year = {2026},
volume = {104},
number = {2},
pages = {130--138},
doi = {10.1111/cen.70059}
}
EUVIMED